HeyJaredDecera Clinical Education Oncology Podcast
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
- Indexed episodes, last 90 days
- 19
- Latest publication
- Sep 22, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 13, 2026
Latest episodes
ASCO 2026 Updates in Metastatic Breast Cancer (opens the original)
Read excerpt
In this podcast, experts review practice-informing data presented at the ASCO 2026 annual conference that may reshape treatment decisions in metastatic breast cancer. The discussion examines ctDNA-guided treatment adaptation for emergent ESR1 mutations in HR-positive/HER2-negative disease, emerging endocrine-based precision strategies targeting ER and PI3K/AKT signaling, and first-line TROP2-directed antibody-drug conjugates in metastatic triple-negative breast cancer. The experts place the SERE
Evolving Role of B7-H3–Directed ADCs in the Extensive-Stage Small-Cell Lung Cancer Treatment Landscape (opens the original)
Read excerpt
The care of patients with extensive-stage (ES) small-cell lung cancer (SCLC) continues to evolve with the continuous release of new clinical evidence. Listen to this podcast with 2 experts discussing current gaps and clinical needs for patients with relapsed ES-SCLC, the scientific rationale for targeting B7-H3 and other tumor-associated antigens in SCLC, the expanding role of antibody–drug conjugates (ADCs) and T-cell engagers in ES-SCLC including recent efficacy and safety data for B7-H3–direc
Targeting CDH6 in Platinum-Resistant Ovarian Cancer: Emerging ADCs, Biomarkers, and Sequencing (opens the original)
Read excerpt
In this podcast episode, experts discuss the scientific rationale and emerging clinical evidence for targeting CDH6 in platinum-resistant ovarian cancer, with a focus on CDH6-directed antibody–drug conjugates (ADCs) such as raludotatug deruxtecan and other investigational agents. The discussion examines CDH6 expression in ovarian tumors, the current limitations of biomarker testing and patient selection, and how ADC characteristics, including target expression, payload, linker properties, and dr
ASCO 2026 Updates in Early Hormone Receptor–Positive Breast Cancer (opens the original)
Read excerpt
In this podcast, experts review 2 of the most important studies presented at the ASCO 2026 annual conference that inform treatment decisions for patients with early-stage hormone receptor–positive/HER2-negative breast cancer. The discussion focuses on the phase III OPTIMA trial, which evaluated Prosigna PAM50-guided chemotherapy selection and the potential for chemotherapy de-escalation in selected patients, with stimulating insights on the role of ovarian function suppression with endocrine the
CELMoDs on the Horizon: A New Chapter in Lymphoma Care (opens the original)
Read excerpt
In this podcast, 2 experts explore the evolving role of CELMoD-based strategies in lymphoma, with a focus on the biologic mechanisms and emerging clinical evidence for golcadomide in diffuse large B-cell lymphoma and follicular lymphoma. Listeners will hear how CELMoDs differ from established immunomodulatory and immune-based therapies, review evidence from ongoing and early-phase studies of golcadomide as monotherapy and in combination regimens, and consider practice-relevant issues including e
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Not enough subject data for this period yet.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.
See coverage about Decera Clinical Education Oncology Podcast